Breaking Finance News

Ionis Pharma (NASDAQ:IONS) stock price target increased to $65.00, issued a research note today by Evercore ISI

Yesterday Ionis Pharma (NASDAQ:IONS) traded 1.22% higher at $47.41. The company’s 50-day moving average is $51.89 and its 200-day moving average is $47.05. The last closing price is up 1.99% from the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same time period. 305,399 shares of the stock traded hands, down from an average trading volume of 1,277,520

In a report released on 8/17/2017 Evercore ISI increased the stock price target of Ionis Pharma (NASDAQ:IONS) to $65.00 indicating a possible upside of 0.37%.

Previously on 8/09/2017, Stifel reported on Ionis Pharma (NASDAQ:IONS) increased the target price from $42.00 to $50.00. At the time, this indicated a possible upside of 0.03%.

See Chart Below

Ionis Pharma (NASDAQ:IONS)

Ionis Pharma has a 52 week low of $24.58 and a 52 week high of $60.01 with a P/E ratio of 230.72 The company’s market cap is currently $0.

In addition to Evercore ISI reporting its stock price target, a total of 9 brokers have issued a research note on the company. The average stock price target is $52.56 with 1 broker rating the stock a strong buy, 5 brokers rating the stock a buy, 5 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 1 broker rating the stock a sell.

General Information About Ionis Pharma (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.